UroGen Pharma Ltd (NASDAQ: URGN) has seen a rise in its stock price by 1.44 in relation to its previous close of 12.48. However, the company has experienced a 10.57% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-11-26 that PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primar.
Is It Worth Investing in UroGen Pharma Ltd (NASDAQ: URGN) Right Now?
Moreover, the 36-month beta value for URGN is 1.07. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for URGN is 36.52M and currently, short sellers hold a 17.64% of that float. On November 28, 2024, URGN’s average trading volume was 577.60K shares.
URGN’s Market Performance
URGN stock saw an increase of 10.57% in the past week, with a monthly gain of 3.35% and a quarterly increase of -9.57%. The volatility ratio for the week is 4.68%, and the volatility levels for the last 30 days are 5.79% for UroGen Pharma Ltd (URGN). The simple moving average for the last 20 days is 5.44% for URGN stock, with a simple moving average of -12.33% for the last 200 days.
Analysts’ Opinion of URGN
Many brokerage firms have already submitted their reports for URGN stocks, with Guggenheim repeating the rating for URGN by listing it as a “Buy.” The predicted price for URGN in the upcoming period, according to Guggenheim is $40 based on the research report published on August 22, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see URGN reach a price target of $10, previously predicting the price at $35. The rating they have provided for URGN stocks is “Hold” according to the report published on February 08th, 2023.
Berenberg gave a rating of “Buy” to URGN, setting the target price at $20 in the report published on April 27th of the previous year.
URGN Trading at 2.38% from the 50-Day Moving Average
After a stumble in the market that brought URGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.84% of loss for the given period.
Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares sank -2.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.36% lower at present.
During the last 5 trading sessions, URGN rose by +10.57%, which changed the moving average for the period of 200-days by -32.48% in comparison to the 20-day moving average, which settled at $12.01. In addition, UroGen Pharma Ltd saw -15.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at URGN starting from Schoenberg Mark, who sale 859 shares at the price of $13.08 back on Sep 09 ’24. After this action, Schoenberg Mark now owns 145,091 shares of UroGen Pharma Ltd, valued at $11,236 using the latest closing price.
Smith Jason Drew, the General Counsel of UroGen Pharma Ltd, sale 1,521 shares at $13.08 during a trade that took place back on Sep 09 ’24, which means that Smith Jason Drew is holding 25,226 shares at $19,895 based on the most recent closing price.
Stock Fundamentals for URGN
Current profitability levels for the company are sitting at:
- -0.94 for the present operating margin
- 0.9 for the gross margin
The net margin for UroGen Pharma Ltd stands at -1.29. The total capital return value is set at -0.31.
Based on UroGen Pharma Ltd (URGN), the company’s capital structure generated 0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -0.79. The debt to equity ratio resting at 4.77. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -63.83 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 5.94. The receivables turnover for the company is 3.92for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.00.
Conclusion
To wrap up, the performance of UroGen Pharma Ltd (URGN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
